Skip to main content
Figure 2 | Journal of Neuroinflammation

Figure 2

From: Therapeutic versus neuroinflammatory effects of passive immunization is dependent on Aβ/amyloid burden in a transgenic mouse model of Alzheimer's disease

Figure 2

Brain Aβ1-42 is decreased in 22 month-old PFA1 treated male mice. A. Aβ1-40 levels were measured from DEA-extracted (soluble proteins, left) and FA-extracted (total proteins, right) brain lysates from vehicle (n = 6) or PFA1-treated (n = 7) female mice following 4 weeks of treatment. Insoluble Aβ levels were calculated as the difference between total and soluble Aβ. There were no significant differences in soluble, insoluble, or total Aβ1-40 levels between vehicle and PFA1-treated female mice. B. Aβ1-42 levels were measured from DEA and FA lysates from the same female mice treated with vehicle or PFA1. There were no significant differences in Aβ1-42 between vehicle and PFA1-treated female mice. C. Aβ1-40 levels were measured from DEA and FA lysates from vehicle (n = 5) or PFA1-treated (n = 7) male mice. There were trends towards decreased soluble (30%), insoluble (16%) and total (17%) Aβ1-40 in PFA1-treated mice. D. Aβ1-42 levels were measured from DEA and FA lysates from vehicle or PFA1-treated male mice following 4 weeks of treatment. PFA1-treated mice exhibited a trend towards decreased soluble Aβ1-42 (32%) and had a significant decrease in insoluble and total Aβ1-42 (48%, p < 0.05, and 47%, p < 0.05, respectively).

Back to article page